Penetração cutânea passiva e iontoforética de propionato de clobetasol incorporado em carreadores lipídicos nanoestruturados

• Autor(a) principal: Silva, Luis Antônio Dantas
• Data de Publicação: 2013
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/0013000004drx
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tde/3009
• topic: Propionato de clobetasol; Retenção cutânea; Nanopartículas lipídicas; Quitosana; Permeação cutânea passiva; Ionotoforesis; Clobetasol propionate; Cutaneous retention; Lipids nanoparticles; Chitosan; Passive cutaneum permeation; FARMACOLOGIA::FARMACOLOGIA GERAL

Clobetasol propionate is one of the most potent topical corticosteroids usually available and has been established the use in treatment of various skin pathology. However its systemic absorption may cause serious side effects. The use of lipids nanocarriers and application of iontophoretic current shown potential to further controlled release of clobetasol propionate and increase their retention in the stratum corneum, thus making its management more effective and safe. In this study an analytical method was developed and validated for quantification of clobetasol propionate in nanocarriers and pig skin, used as model membranes in vitro permeation studies. Nanostructured lipid carriers (NLC) were obtained by dilution of microemulsion and chitosan-coated NLC (NLC-Ch) by the dripping of NLC in chitosan solution. The developed nanocarriers were characterized to mean diameter, polydispersity index, zeta potential, drug loading, recovery and encapsulation efficiency. The in vitro release and permeation profile of clobetasol free and nanoencapsulated was evaluated using Franz cells. The nanocariers obtained of 125 nm and uniform size distribution, whit PdI 0,25. The increase in size of NLC-Ch and the inverting the value of zeta potential, suggest that there was a coating of the CLN by chitosan, though interaction of charges. The NLC and NLC-Ch showed recovery values greater than 80% and encapsulation efficiency than 90%. The release profile of clobetasol from the developed formulations showed a controlled release with 35% in 24 hours of study. The nanoenapsulation of clobetasol in the NLC-Ch and NLC resulted in retention increased in the stratum corneum of 9.2 an 7.8 fold, respectively, compared to free drug. The retention of the clobetasol in the stratum corneum was 4 and 2 times higher when electric current was applied to the formulation CLNQ, compared to the free drug and encapsulated in NLC, respectively. The accumulation of the drug in the stratum corneum, promoted by lipid carriers, shows that these systems are effective for potential topical delivery to minimize the permeation of the drug into the bloodstream and reduces the side effects.